VGX 3100

Drug Profile

VGX 3100

Alternative Names: Human papillomavirus vaccine-VGX Pharmaceuticals; VGX-3100

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Clinical Phase Unknown Head and neck cancer

Most Recent Events

  • 13 Feb 2017 VGX 3100 licensed to ApolloBio in China, Hong Kong, Macao, Taiwan for the treatment of Human papillomavirus infections
  • 17 Sep 2015 Updated efficacy data from a phase II trial in Cervical intraepithelial neoplasia released by Inovio Pharmaceuticals
  • 17 Sep 2015 Inovio plans a phase III trial for Cervical intraepithelial neoplasia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top